Comparing Treatments for Refractory Overactive Bladder: Bladder Denervation vs Botulinum Toxin Injections
Status:
COMPLETED
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to compare the effectiveness and safety of two treatments for refractory overactive bladder in adult women.
The main questions it aims to answer are:
* Does selective bladder denervation using radiofrequency ablation improve overactive bladder symptoms more effectively than intravesical Onabotulinum toxin A injections?
* What are the safety profiles of each treatment?
Researchers will compare selective bladder denervation using radiofrequency ablation to intravesical Onabotulinum toxin A injections to determine which treatment is more effective and tolerable for patients whose symptoms persist despite behavioral and medical therapies.
Participants will:
* Be women aged 18 and older diagnosed with overactive bladder who did not benefit from at least two prior medical treatments for 3 months or were unable to tolerate those treatments.
* Be randomly assigned to receive either radiofrequency ablation or Onabotulinum toxin A treatment.
* Attend follow-up visits at weeks 2, 4, and 12 over a 3-month period, during which symptom improvement will be assessed using validated questionnaires and side effects will be monitored through imaging, blood, and urine tests.